Related Experiment Video

Updated: Jun 22, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

Subbarao V Madhunapantula1, Gavin P Robertson

  • 1Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA, USA.

Pigment Cell & Melanoma Research
|June 5, 2009
PubMed

Insights

Genetic changes in melanoma deregulate key signaling pathways. This review focuses on the phosphoinositide-3-kinase (PI3K) pathway, specifically PTEN and Akt3, highlighting their roles in melanoma development and therapeutic targeting.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Melanoma development involves genetic alterations in melanocytes.
  • Aberrant gene activity drives melanoma progression.
  • Phosphoinositide-3-kinase (PI3K) and mitogen-activated protein (MAP) kinase pathways are crucial in melanoma.

Purpose of the Study:

  • To review the PI3K pathway's role in melanoma.
  • To focus on PTEN and Akt3 proteins within the PI3K pathway.
  • To discuss deregulation mechanisms and therapeutic strategies targeting these proteins in melanoma.

Main Methods:

  • Literature review of PI3K pathway signaling in melanoma.
  • Analysis of PTEN and Akt3 roles in melanoma pathogenesis.
  • Examination of therapeutic implications for targeting the PI3K cascade.

Main Results:

  • PI3K and MAP kinase pathways regulate critical cellular functions like proliferation and survival in melanoma.
  • PTEN and Akt3 are key PI3K pathway members implicated in melanoma development.
  • Deregulation of PTEN and Akt3 contributes to melanoma aggressiveness.

Conclusions:

  • Targeting the PI3K pathway, particularly PTEN and Akt3, is essential for effective advanced-stage melanoma treatment.
  • Understanding PTEN and Akt3 deregulation mechanisms can lead to novel therapeutic approaches.
  • Combined targeting of PI3K and MAP kinase pathways may offer long-term melanoma treatment benefits.

More Related Videos

A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...